Comparative Study of Triglyceride Level in Ischemic Heart Disease Patients in different age groups of Patients in south east Rajasthan

  • Darab Singh Underwal univ
  • Sushma Pandey
  • Deepak Gupta


Backgrounds: Elevated body triglycerides have been implicated as a risk factor of ischemic heart disease (IHD).

Objectives: To study the association of serum triglyceride with ischemic heart disease and to assess the relationship of serum triglyceride with other established conventional risk factors.

Methods: A cross sectional case-control study of 75 cases of IHD and 75 controls without having any evidence of IHD/CHD between age group 30-70 years. Serum triglyceride levels were estimated by using Colorimetric Method and other risk factors by enzymatic methods.

Results: Mean serum triglyceride (263.674 ± 89.029mg/dl) was significantly higher in cases than controls (98.833 ± 62.682mg/dl). Amongst the patients of IHD, significantly higher level of Serum triglyceride was found in diabetics (340.63±90.78mg/dl) than non-diabetics (225.19±58.30mg/dl), male elderly (>60years of age) smokers (304.20±88.60mg/dl) compared to non smoker (206.37±48.88mg/dl), elderly male with high (>150mg/dl) LDL (323.48±86.73mg/dl) compared to patients with normal (<150mg/dl) LDL (249.33±66.12 mg/dl). Similarly male patients of IHD with high (>40mg/dl) VLDL had significantly higher serum triglyceride (326.49±77.95mg/dl) compared to male patients with normal (<40mg/dl) VLDL (257.18±85.46mg/dl).

Conclusion: High serum triglyceride level (>200mg/dl) may provide a cost effective tool for predicting an impending ischemic heart disease especially in diabetic patients, male elderly smokers, elderly males with high LDL, male patients of ischemic heart disease with high VLDL level.

Keywords: ischemic heart disease (IHD), conventional risk factors, Serum triglyceride


Download data is not yet available.


1. NIH Consensus Development Panel on Triglyceride. High-Density Lipoprotein, and Coronary Heart Disease. NIH Consensus Conference: Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease. JAMA. 1993; 269:505–10.
2. Chockalingam A, Balagner-vintro I: Impending Global Pandemic of cardiovascular diseases; challanges and opportunities for the prevention and control of cardiovascular diseases in developing countries and economics in transition Barcelona, Prous Science, 1999.
3. Shepherd J, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med. 1995; 333:1301-7.
4. Schonfeld G. Inherited disorders of lipid transport. Endocrinol Metab Clin North Am. 1990; 19:229–57.
5. Jacobs DR, Barrett-Connor E. Retest reliability of plasma cholesterol and triglyceride: the Lipid Research Clinics Prevalence Study. Am J Epidemiol. 1982; 116:878–85. [PubMed: 7148814]
6. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007; 115:450–8. [PubMed: 17190864]
7. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996; 3(2):213–9. [PubMed: 8836866]
8. Asia Pacific Cohort Studies Collaboration. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004; 110:2678–86. [PubMed: 15492305]
9. Di Angelantonio E, Sarwar N, Perry P, et al. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins and risk of vascular disease. JAMA. 2009; 302:1993–2000. [PubMed: 19903920]
10. Carey VJ, Bishop L, Laranjo N, et al. Contribution of High Plasma Triglycerides and Low High Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control. Am J Cardiol. 2010; 106:757–63. [PubMed: 20816113]
11. Assmann G, Cullen P, Schulte H. Non-LDL-related dyslipidaemia and coronary risk: a case– control study. Diab Vasc Dis Res. 2010; 7(3):204–12. [PubMed: 20643700]
12. Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation. 2002; 105:1424–8. [PubMed: 11914249] Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008; 51:724–30. [PubMed: 18279736]
13. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation. 2002; 106(25):3143–421. [PubMed: 12485966]
14. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb.1991; 11:2-14.
15. Garber AM, Avins AL. Triglyceride concentration and coronary heart disease [editorial; comment] [see comments]. BMJ. 1994;309:2–3.
389 Views | 0 Downloads
How to Cite
Underwal, D. S., S. Pandey, and D. Gupta. “Comparative Study of Triglyceride Level in Ischemic Heart Disease Patients in Different Age Groups of Patients in South East Rajasthan”. International Journal of Drug Regulatory Affairs, Vol. 6, no. 2, June 2018, pp. 92-99, doi:10.22270/ijdra.v6i2.256.